Brief Summary
The purpose of this study is to assess the effect of delivering all anti-cancer medications during initial systemic therapy on outcomes in those undergoing treatment for metastatic colorectalrelating to the colon or rectum in the large bowel/intestine cancera disease where abnormal cells split without control and spread to other nearby body tissue and/or organs.
Intervention/Treatment
- Drug: mFOLFOX6
- Drug: Oxaliplatin
- Drug: Leucovorin
- Drug: Fluorouracil
- Drug: FOLFIRI
- Drug: CAPOX
- Drug: Capecitabine
- Drug: CAPIRI
- Drug: Irinotecan
Inclusion Criteria
- Signed informed consenta process in which a patient receives detailed information about a procedure or treatment, including its potential risks, benefits, and alternatives. The patient then has the opportunity to understand the information and voluntarily agree to the procedure or treatment. obtained prior to any study specific procedures and willingness to comply with study requirements.
- Age greater than or equal to 18 years.
- Histologically confirmed, metastatic colorectal adenocarcinomacancer arising from mucus-producing glands in organs treated with less than or equal to 2 cycles of doublet chemotherapya cancer treatment that uses drugs to kill or slow the growth of cancer cells, while minimising damage to healthy cells.
- ECOG performance status of 0-2.
- Life expectancy of greater than or equal to 3 months.
- Adequate major organ function to receive doublet chemotherapy as judged by the treating clinician.
- No contraindication to any of the 3 cytotoxic agents (5FU, oxaliplatin and irinotecan).
- Recent imagingtests that create detailed images of areas inside the body of chest, abdomenstomach, stomach area, belly and pelvis. It is recommended that this should be within 4 weeks of first chemotherapy dosethe amount of medication taken (no more than 8 weeks).
Please note: Every patient enrolled in the study is then entered in the TRACC Registry to enable the data collection for the study.